Tonix Pharmaceuticals Holding announced it is filing an NDA submission in 2H 2024 and laying plans for the commercial launch of Tonmya for the management of fibromyalgia, assuming approval by the FDA in 2H 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
- Tonix Pharma Updates Investors on CD45 Candidate Developments
- Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
- Tonix Pharmaceuticals to sell 7.097M shares at 57c in public offering
- Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
- Tonix Pharmaceuticals Announces Proposed Public Offering